🔍
Large-scale Epigenomic Reprogramming Links Anabolic Glucose Metabolism to Distant Metastasis during the Evolution of Pancreatic Cancer Progression
Case ID:
C14322
Report of Invention:
9/26/2016
Web Published:
2/8/2024
Unmet Need
Pancreatic ductal adenocarcinoma (PDAC) is projected to be the second leading cause of cancer death in the western world by 2020. Subclonal populations that emerge and drive metastatic progression of the disease are associated with high mortality rates among patients. Blocking the tumorigenic potential of metastatic sites is key to improving current clinical outcomes. Epigenetic changes driving this disease were identified and targeted through inhibition of a key glucose metabolism pathway. This approach could represent a novel and effective therapeutic strategy for metastatic PDAC. Key features:
Methods for identifying metastatic propensity in primary tumors
Novel strategy targeting metastatic disease
Achieved selective reversal o f disease-associated changes
Blocked tumorigenic potential of distant metastatic sites
Technology Overview
During the progression of pancreatic ductal adenocarcinoma (PDAC), heterogeneous subclonal populations emerge that drive primary tumor growth, local-regional spread, distant metastasis, and patient death. Johns Hopkins researchers observed that epigenetic reprogramming was driven by a branch of anabolic glucose metabolism. Excitingly, the targeting of this branch yielded a selective reversal of reprogrammed chromatin and blocked tumorigenic potential of distant metastatic subclones. This invention constitutes a novel method of targeting the metastatic progression of highly fatal PDAC.
Stage of Development
Discovery. Looking for partners to develop and commercialize novel metastatic detection and therapeutic strategies for preventing, delaying, or reversing metastatic growth of PDAC.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Patent Status
Large-scale Epigenomic Reprogramming Links Anabolic Glucose Metabolism to Distant Metastasis during the Evolution of Pancreatic Cancer Progression
PCT: Patent Cooperation Treaty
European Patent Office
17859197.0
10/5/2017
Pending
Large-scale Epigenomic Reprogramming Links Anabolic Glucose Metabolism to Distant Metastasis during the Evolution of Pancreatic Cancer Progression
PCT: Patent Cooperation Treaty
Japan
2019-518463
7239468
10/5/2017
3/6/2023
10/5/2037
Granted
LARGE-SCALE EPIGENOMIC REPROGRAMMING LINKS ANABOLIC GLUCOSE METABOLISM TO DISTANT METASTASIS DURING THE EVOLUTION OF PANCREATIC CANCER PROGRESSION
PCT: Patent Cooperation Treaty
United States
16/340,069
11,795,510
4/5/2019
10/24/2023
10/5/2037
Granted
LARGE-SCALE EPIGENOMIC REPROGRAMMING LINKS ANABOLIC GLUCOSE METABOLISM TO DISTANT METASTASIS DURING THE EVOLUTION OF PANCREATIC CANCER PROGRESSION
DIV: Divisional
United States
18/229,064
8/1/2023
Pending
Direct Link:
https://jhu.technologypublisher.com/technology/53248
Inventors:
Category(s):
Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology, Clinical and Disease Specializations > Oncology > Pancreatic Cancer,
Get custom alerts for techs in these categories/from these inventors:
Subscribe for JHTV Updates
For Information, Contact:
Nakisha Holder
nickki@jhu.edu
410-614-0300
Save This Technology:
Bookmark this page
Download as PDF
JHTV Home
|
Search
|
Login/Subscribe
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by
Inteum